Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DNA Ginkgo Bioworks	$7.84 -3.2%	$8.33	$5.00 ▼ $45.20	$454.70M	1.34	1.50 million shs	1.14 million shs
GHRS GH Research	$9.10 +4.6%	$11.02	$6.00 ▼ $20.50	$473.46M	0.84	170,612 shs	190,763 shs
RAPT RAPT Therapeutics	$0.79 -1.3%	$1.12	$0.75 ▼ $8.58	$104.35M	-0.29	1.27 million shs	781,946 shs
URGN UroGen Pharma	$9.67 -6.9%	$10.49	$8.94 ▼ $20.70	$445.73M	0.8	511,147 shs	741,549 shs

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DNA Ginkgo Bioworks	-3.27%	+7.11%	+7.70%	-27.55%	-83.11%
GHRS GH Research	+4.60%	+5.08%	-14.15%	+2.48%	-17.20%
RAPT RAPT Therapeutics	-1.32%	-7.00%	-27.48%	-34.13%	-90.17%
URGN UroGen Pharma	-6.93%	+2.98%	-16.13%	-5.84%	-32.09%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DNA Ginkgo Bioworks	0.6493 of 5 stars	0.8	1.0	0.0	1.9	2.5	1.3
GHRS GH Research	2.42 of 5 stars	4.5	2.0	0.0	0.6	2.5	0.0
RAPT RAPT Therapeutics	3.6106 of 5 stars	3.1	1.0	4.2	2.4	1.7	1.3
URGN UroGen Pharma	4.2742 of 5 stars	4.5	2.0	4.5	2.6	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DNA Ginkgo Bioworks	1.60	Reduce	$4.58	-41.61% Downside
GHRS GH Research	3.00	Buy	$30.86	239.09% Upside
RAPT RAPT Therapeutics	2.11	Hold	$4.00	406.01% Upside
URGN UroGen Pharma	3.00	Buy	$32.86	239.78% Upside

Current Analyst Ratings Breakdown

Latest RAPT, URGN, DNA, and GHRS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/17/2025	URGN UroGen Pharma	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$22.00 ➝ $16.00
4/16/2025	URGN UroGen Pharma	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$23.00
3/13/2025	GHRS GH Research	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$32.00
3/11/2025	URGN UroGen Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$64.00 ➝ $55.00
3/10/2025	RAPT RAPT Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
3/10/2025	URGN UroGen Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00
3/7/2025	GHRS GH Research	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$31.00
2/27/2025	GHRS GH Research	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$18.00 ➝ $32.00
2/25/2025	URGN UroGen Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$64.00 ➝ $64.00
2/19/2025	URGN UroGen Pharma	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$31.00
2/18/2025	URGN UroGen Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00

(Data available from 4/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DNA Ginkgo Bioworks	$227.04M	2.00	N/A	N/A	$21.93 per share	0.36
GHRS GH Research	N/A	N/A	N/A	N/A	N/A	N/A
RAPT RAPT Therapeutics	$1.53M	68.20	N/A	N/A	$4.27 per share	0.19
URGN UroGen Pharma	$90.40M	4.93	N/A	N/A	($2.78) per share	-3.48

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DNA Ginkgo Bioworks	-$892.87M	-$10.68	N/A	N/A	N/A	-298.78%	-58.54%	-34.24%	5/8/2025 (Estimated)
GHRS GH Research	-$35.59M	-$0.75	N/A	N/A	N/A	N/A	-20.29%	-19.49%	5/2/2025 (Estimated)
RAPT RAPT Therapeutics	-$116.80M	-$3.11	N/A	N/A	N/A	N/A	-89.10%	-76.13%	5/8/2025 (Estimated)
URGN UroGen Pharma	-$102.24M	-$3.23	N/A	N/A	N/A	-129.11%	N/A	-47.94%	5/12/2025 (Estimated)

Latest RAPT, URGN, DNA, and GHRS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	URGN UroGen Pharma	-$0.83	N/A	N/A	N/A	$22.71 million	N/A
5/8/2025	Q1 2025	DNA Ginkgo Bioworks	-$1.23	N/A	N/A	N/A	N/A	N/A
5/8/2025	Q1 2025	RAPT RAPT Therapeutics	-$0.31	N/A	N/A	N/A	N/A	N/A
5/2/2025	Q1 2025	GHRS GH Research	-$0.61	N/A	N/A	N/A	N/A	N/A
3/10/2025	Q4 2024	URGN UroGen Pharma	-$0.69	-$0.80	-$0.11	-$0.80	$25.25 million	$24.57 million
3/6/2025	Q4 2024	RAPT RAPT Therapeutics	-$0.45	-$1.14	-$0.69	-$1.14	N/A	N/A
2/27/2025	Q4 2024	GHRS GH Research	-$0.23	-$0.17	+$0.06	-$0.17	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DNA Ginkgo Bioworks	N/A	N/A	N/A	N/A	N/A
GHRS GH Research	N/A	N/A	N/A	N/A	N/A
RAPT RAPT Therapeutics	N/A	N/A	N/A	N/A	N/A
URGN UroGen Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DNA Ginkgo Bioworks	N/A	5.79	5.79
GHRS GH Research	N/A	15.83	15.83
RAPT RAPT Therapeutics	N/A	9.90	9.90
URGN UroGen Pharma	4.77	9.00	8.77

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DNA Ginkgo Bioworks	78.63%
GHRS GH Research	56.90%
RAPT RAPT Therapeutics	99.09%
URGN UroGen Pharma	91.29%

Insider Ownership

Company	Insider Ownership
DNA Ginkgo Bioworks	9.72%
GHRS GH Research	41.60%
RAPT RAPT Therapeutics	6.60%
URGN UroGen Pharma	5.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DNA Ginkgo Bioworks	640	58.03 million	51.89 million	Optionable
GHRS GH Research	10	52.03 million	30.38 million	Optionable
RAPT RAPT Therapeutics	80	132.01 million	32.65 million	Optionable
URGN UroGen Pharma	200	46.09 million	22.26 million	Optionable

RAPT, URGN, DNA, and GHRS Headlines

Recent News About These Companies

Scotiabank Initiates Coverage on UroGen Pharma (NASDAQ:URGN)

April 18 at 8:05 AM | marketbeat.com

Analysts Are Bullish on These Healthcare Stocks: Urogen Pharma (URGN), Ligand Pharma (LGND)

April 17 at 5:32 PM | markets.businessinsider.com

UroGen Pharma initiated with an Outperform at Scotiabank

April 17 at 12:30 PM | markets.businessinsider.com

Scotiabank Initiates Coverage of UroGen Pharma (URGN) with Sector Outperform Recommendation

April 17 at 12:30 PM | msn.com

This UroGen Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

April 16 at 11:41 AM | benzinga.com

ExodusPoint Capital Management LP Acquires New Shares in UroGen Pharma Ltd. (NASDAQ:URGN)

April 15 at 4:21 AM | marketbeat.com

UroGen: June 13 PDUFA For Potential Bladder Cancer Blockbuster Sets Up Strong Buy

April 12, 2025 | seekingalpha.com

UroGen Pharma Ltd. (NASDAQ:URGN) Receives Consensus Recommendation of "Buy" from Analysts

April 12, 2025 | marketbeat.com

Trexquant Investment LP Has $1.84 Million Stock Position in UroGen Pharma Ltd. (NASDAQ:URGN)

April 11, 2025 | marketbeat.com

Why UroGen Pharma Ltd.’s (URGN) Stock Is Down 10.84%

April 10, 2025 | aaii.com

UroGen Pharma Ltd. (NASDAQ:URGN) Receives Consensus Recommendation of "Buy" from Brokerages

April 10, 2025 | americanbankingnews.com

UroGen Pharma (NASDAQ:URGN) Stock Price Up 4.5% - Here's Why

April 4, 2025 | marketbeat.com

Rosalind Advisors Inc. Makes New $9.27 Million Investment in UroGen Pharma Ltd. (NASDAQ:URGN)

March 23, 2025 | marketbeat.com

UroGen Pharma (NASDAQ:URGN) Stock Price Up 3.6% - Time to Buy?

March 21, 2025 | marketbeat.com

Privium Fund Management B.V. Purchases Shares of 27,691 UroGen Pharma Ltd. (NASDAQ:URGN)

March 20, 2025 | marketbeat.com

UroGen Pharma price target lowered to $55 from $64 at H.C. Wainwright

March 11, 2025 | markets.businessinsider.com

UroGen Pharma Ltd. (NASDAQ:URGN) Q4 2024 Earnings Call Transcript

March 11, 2025 | insidermonkey.com

UroGen Pharma sees FY25 operating expenses $215M-$225M

March 10, 2025 | markets.businessinsider.com

Urogen pharma outlines $1B revenue potential for UGN-102 with June 2025 launch target

March 10, 2025 | msn.com

UroGen Pharma Ltd. (URGN) Q4 2024 Earnings Call Transcript

March 10, 2025 | seekingalpha.com

Urogen Pharma (URGN) Reports Q4 Loss, Lags Revenue Estimates

March 10, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RAPT, URGN, DNA, and GHRS Company Descriptions

Ginkgo Bioworks NYSE:DNA

$7.84 -0.26 (-3.15%)

Closing price 04/17/2025 03:59 PM Eastern

Extended Trading

$7.88 +0.04 (+0.51%)

As of 04/17/2025 05:56 PM Eastern

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

GH Research NASDAQ:GHRS

$9.10 +0.40 (+4.60%)

Closing price 04/17/2025 04:00 PM Eastern

Extended Trading

$9.02 -0.08 (-0.93%)

As of 04/17/2025 04:05 PM Eastern

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

RAPT Therapeutics NASDAQ:RAPT

$0.79 -0.01 (-1.32%)

Closing price 04/17/2025 04:00 PM Eastern

Extended Trading

$0.78 -0.01 (-1.08%)

As of 04/17/2025 05:33 PM Eastern

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company

UroGen Pharma NASDAQ:URGN

$9.67 -0.72 (-6.93%)

Closing price 04/17/2025 04:00 PM Eastern

Extended Trading

$9.68 +0.01 (+0.05%)

As of 04/17/2025 04:05 PM Eastern

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time